The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019 No. 744

Amendment of regulation 33 (notification of suspected unexpected serious adverse reactions)U.K.

14.—(1) Regulation 33 is amended as follows.

(2) Omit paragraph (1)(b)(ii).

(3) Omit paragraph (3)(b).

(4) Omit paragraph (4).

(5) Omit paragraph (6)(b), and the “and” immediately preceding it.

Commencement Information

I1Reg. 14 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1